Join to View Full Profile
35 Cambridgepark DrCambridge, MA 02140
Phone+1 617-665-7796
Dr. Berkenblit is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Harvard Medical SchoolClass of 1996
Certifications & Licensure
MA State Medical License 1998 - 2026
Clinical Trials
- Open-label Study of IMGN779 in Adult Patients With Relapsed/Refractory CD33-positive Acute Myeloid Leukemia Start of enrollment: 2016 Mar 01
Publications & Presentations
PubMed
- 4 citationsPopulation pharmacokinetics of mirvetuximab soravtansine in patients with folate receptor-α positive ovarian cancer: The antibody-drug conjugate, payload and metabolite.Ya-Ping Tu, Eva Hanze, Fengying Zhu, H Maxime Lagraauw, Callum M Sloss
British Journal of Clinical Pharmacology. 2024-02-01 - 104 citationsMirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer.Kathleen N Moore, Antoine Angelergues, Gottfried E Konecny, Yolanda García, Susana Banerjee
The New England Journal of Medicine. 2023-12-07 - 163 citationsPhase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I.Kathleen N. Moore, Amit M. Oza, Nicoletta Colombo, Ana Oaknin, Giovanni Scambia
Annals of Oncology. 2021-06-01
Press Mentions
Research Spotlight by Dr. Anna Berkenblit: July 2025July 23rd, 2025- Research Spotlight by Dr. Anna Berkenblit: June 2025June 23rd, 2025
- Research Spotlight by Dr. Anna Berkenblit: May 2025May 13th, 2025
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
